NEON Therapeutics is focused on unlocking the full potential of the immune system to recognize and attack cancer.
Neon Therapeutics is a clinical-stage biopharmaceutical company. It is focused in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. The company's pipeline products are NEO-PV-01, NEO-PTC-01, and NEO-SV-01.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Dec 5, 2017 | Series B | $36M | 1 | — | — | Detail |
Jan 5, 2017 | Series B | $70M | 1 | — | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Inbio Ventures | — | Series B |